
Staying One Step Ahead of Resistance
How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.

Memory B cells play a key role in adapting to new coronavirus variants
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Xie E, Schubert M, Reeb J, Seligmann B, Schaks M, Müsken M, Steffen A, Stradal T, Haid S, Rottner K, Sieben C
Baydemir I, Nikolka F, Bulut Ö, Ferreira A, Kilic G, Geckin B, Kramer R, Cuenca-Escalona J, Floor E, Báez-Magaña M, Matzaraki V, Deckers J, Anbergen T, van Elsas Y, Beldman T, Moorlag S, Charlotte J de Bree L, Spanou V, Andriopoulou T, Li Y, Karagianni E, Novakovic B, Sohrabi Y, Joosten L, Hiller K, Domínguez-Andrés J
Tapken I, Rahmel-Stein K, Ehlers C, Cieri F, Detering N, Schüning T, Bjelica B, Mindermann C, Neuhoff S, Schmitt L, Leo M, Hagenacker T, Illsinger S, Di Schiavi E, Graalmann T, Petri S, Kalinke U, Claus P
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
The CoViPa consortium uses computer-assisted high-throughput virus discovery and evolutionary analyses to identify RNA viruses with high spillover risk and potential animal host reservoirs and to investigate new pathogenicity factors.
Prof. Naglaa Shoukry
University of Montreal
"Single-Cell RNA Sequencing Analysis of CD8+ T Cell-Mediated Protective Immunity During HCV Reinfection"
Prof. Heidi Drummer
University of Melbourne, Burnet Institute
"Development of hepatitis C vaccine candidates to generate neutralizing antibodies"
"Why is knowledge in regulatory science important for translational medicine and basic science?"

